QIAGEN Achieves Milestone with Kits Used to Process Over Three Billion Biological Samples to Date BioBuzz

  • Milestone highlights the company’s global leadership in sample preparation
  • The company’s NGS tests have also reached the milestone of one million samples tested since 2015
  • New Kits and Instruments to Strengthen QIAGEN’s Position in Most Critical Area of ​​Molecular Testing

August 23, 2021, GERMANTOWN, Maryland and HILDEN, Germany – (BUSINESS WIRE) – QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the number of biological samples processed with consumable kits has exceeded the three billion mark – a record that underscores its leadership in enabling molecular laboratories to acquire valuable knowledge in research, disease control and forensics.

This milestone particularly highlights QIAGEN’s exceptional position in sample preparation, the most critical step in molecular testing at which DNA, RNA or proteins are extracted from human samples. QIAGEN Sample Preparation Kits have set the standard in sample extraction and have gained over 200,000 references in academic studies. With over 500 consumable kits and automated systems such as QIAsymphony, QIAcube Connect, QIAcube HT and EZ1, QIAGEN is the most trusted brand in sample preparation.

“Crossing the three billion threshold truly demonstrates QIAGEN’s leadership in molecular testing,” said Thierry Bernard, CEO of QIAGEN. “QIAGEN Sample Extraction Kits can be found in virtually all types of academic, pharmaceutical, forensic and clinical laboratories around the world. They are essential for advancing scientific discoveries, identifying diseases and many other applications that improve life. Our constant innovation to facilitate the processing of increasingly difficult sample types will continue to strengthen our market value. “

QIAGEN has many new products in development, including kits in the highly innovative field of liquid biopsy – in which body fluids such as blood, saliva or urine replace the need for biopsied tissue samples – and the emerging field of microbiome research – the study of the composition of microbial communities and its influence on the onset, progression or therapeutic response of disease in a wide range of disorders. The company also plans to launch the EZ2 Connect for research, human identification and molecular diagnostic applications, as well as other new instruments to continue to drive automation in the area of ​​sample preparation.

Sample technology is one of QIAGEN’s five growth pillars, alongside QuantiFERON immune response technology, the NeuMoDx integrated PCR system, the QIAstat-Dx syndromic assay solution and the QIAcuity digital PCR portfolio. Announced in August 2020, this focused long-term growth strategy aims to establish or strengthen QIAGEN as a top three player in each of these areas – and thus maintain the company’s leadership in molecular analysis in research and clinical trial applications.

QIAGEN sampling technologies are integrated with QIAGEN assays and bioinformatics solutions to enable customers to unlock valuable molecular information – or seamlessly move from a raw biological sample to the final interpreted result, as, for example, in the next-generation sequencing (NGS) of DNA or RNA, where QIAGEN has taken another important step.

“Since entering the NGS Universal Consumables market in 2015, more than one million samples have been processed using our NGS panels,” said Thomas Schweins, Senior Vice President Business Area QIAGEN Life Sciences. “This achievement is a clear testament to our commitment to serving customers from Sample to Insight, as the vast majority of laboratories that use QIAGEN panels also use QIAGEN’s sample preparation technologies and bioinformatics solutions.

The NGS allows clinicians and researchers to quickly test hundreds of genes in a sample at the same time. In the treatment of cancer, for example, it allows doctors to effectively identify genetic mutations that can be used to target the specific type of cancer. The growing number of these potentially important target mutations has given rise to personalized medicine, in which test results guide treatment decisions.

QIAGEN’s strong market position in this area is primarily due to the company’s ability to provide bespoke NGS testing. QIAGEN’s Enterprise Genomics Services unit supports the world’s leading cancer screening institutions in designing personalized cancer panels based on individual customer needs and evolving scientific findings. It leverages QIAGEN’s cutting-edge bioinformatics solutions, including the QIAGEN Knowledge Base, providing access to the world’s largest reservoir of biological and clinical discoveries with over two million unique variants selected by experts from over 300 000 scientific articles. Over 2 million NGS patient tests have been interpreted with QIAGEN Clinical Insight (QCI), the company’s clinical decision support platform.

For more information on QIAGEN’s sample-to-insight technologies, please visit https://qiagen.com


QIAGEN NV, a Netherlands-based holding company, is the world’s leading provider of Sample to Insight solutions that enable customers to gain valuable molecular information from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to yield relevant and actionable information. Automation solutions connect them in transparent and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in the fields of molecular diagnostics (human health) and life sciences (universities, pharmaceutical R&D and industrial applications, mainly forensics). As of June 30, 2021, QIAGEN employed approximately 5,900 people at more than 35 locations around the world. Further information is available at http://www.qiagen.com

Forward-looking statement

Certain statements contained in this press release may be considered as forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as ‘fine. To the extent that any of the statements contained herein regarding QIAGEN’s products, including products used in the COVID-19 pandemic response, launch and development schedule, marketing approvals and / or regulatory, financial and operating outlook, growth and expansion, collaborative markets, strategy or operating results, including, without limitation, its expected adjusted net sales and adjusted earnings results diluted, are forward-looking, these statements are based on current expectations and assumptions which involve a number of uncertainties and risks. These uncertainties and risks include, but are not limited to, the risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and reliance on logistics), variability in results operations and allocations between customer categories; commercial development of markets for our products to academic, pharmaceutical, applied testing and molecular diagnostics customers; changing relationships with customers, suppliers and strategic partners; competetion; rapid or unexpected technological changes; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, level and timing of customer financing, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from competitive products; market acceptance of new QIAGEN products and integration of acquired technologies and businesses; government actions, global or regional economic developments, weather or transport delays, natural disasters, political or public health crises, including the extent and duration of the COVID-19 pandemic and its impact on demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that the expected benefits associated with recent or ongoing acquisitions will not materialize as expected; and other factors discussed under the heading “Risk Factors” in Item 3 of our most recent Annual Report on Form 20-F. For more information, please refer to the discussions in reports that QIAGEN has filed with or provided to the United States Securities and Exchange Commission.

The next two tabs modify the content below.

BioBuzz is the only media and events brand dedicated solely to the regional biotechnology and life sciences industry

Previous US stocks open higher to undo last week's rout
Next No clear timeline for US-Kenya trade deal after key meeting

No Comment

Leave a reply

Your email address will not be published.